SCD and metabolic dysfunction-associated steatohepatitis: Aramchol, a partial inhibitor of hepatic stearoyl-CoA desaturase (SCD1), has improved steatohepatitis in animal models and has reduced steatosis in patients with NASH in a clinical trial15.